A comparative study of the hypolipidaemic effects of a new polysaccharide, mannan <i>Candida albicans</i> serotype A, and atorvastatin in mice with poloxamer 407-induced hyperlipidaemia

Abstract

It is suggested that mannan serotype A, like β-glucan, may represent another hypolipidaemic agent, which could potentially be used as an adjunctive therapy with conventional antihyperlipidaemic drugs (statins and fibrates) in humans.